Prati, F.; de Simone, A.; Bisignano, P.; Armirotti, A.; Summa, M.; Pizzirani, D.; Scarpelli, R.; Andrisano, V.; Perez-Castillo, A.; Monti, B.; Massenzio, F.; Polito, L.; Racchi, M.; Favia, A. D.; Bottegoni, G.; Martinez, A.; Bolognessi, M. L.; Cavalli, A.
[2015]. Multitarget drug discovery for Alzheimer’s disease; triazinones as the first dual BACE1/GSK-3β fragment hits Angew. Chem. Int. Ed. Engl. 2015, 54, 1578-1582.
Mestre, L.; Morales-García, J. A.; Redondo, M.; Perez, C.; Alonso-Gil, S.; Perez-Castillo, A.; Gil, C.; Martinez, A.; Guaza, C.
[2015]. Inhibitors of phosphodiesterase-7 as novel drugs for treatment of multiple sclerosis Br. J. Pharmacol. 2015, 172, 4277-4290
Morales-García, J. A.; Alonso-Gil, S.; Gil, C.; Martínez, A.; Santos, A.; Perez-Castillo, A.
[2015]. Phosphodiesterase 7 inhibition induces dopaminergic neurogenesis in hemiparkinsonian rats. Stem Cells Transl. Med. 2015, 4, 565-574.
Pérez, C.; Ruiz del Castillo, M. L.; Gil, C.; Blanch, G. P.; Flores, G.
[2015]. Supercritical Fluid Extraction of grape seeds: Extract chemical composition, antioxidant activity and inhibition of nitrite production in LPS-stimulated Raw 264.7 cell. Food Funct. 2015, 6, 2607-2613
García, A. M.; Jung, N.; Gil, C.; Nieger, M.; Bräse, S.
[2015]. Solid phase synthesis of functionalized indazoles using triazenes – Scope and limitations. RSC Adv. 2015, 5, 65540-65545
Pérez, D. I.; Martinez, A.; Gil, C.; Campillo, N. E.
[2015]. From bitopic inhibitors to multitarget drugs for Alzheimer’s disease future treatment. Curr. Med. Chem. 2015, 22, 3789-3806
Cahlíková, L.; Pérez, D.I.; Štěpánková, Š.; Chlebek, J.; Šafratová, M.; Hošt'álková, A.; Opletal, L.
[2015]. In vitro inhibitory effects of 8-O-demethylmaritidine and undulatine on acetylcholinesterase and their predicted penetration across the blood-brain barrier. J. Nat. Prod. 2015, 78,1189-1192
Moreira, D. N.; Fresno, N.; Pérez-Fernández, R.; Frizzo, C. P.; Goya, P.; Marco, C.; Martins, M. a. P.; Elguero, J.
[2015]. Brønsted acid–base pairs of drugs as dual ionic liquids: NMR ionicity studies. Tetrahedron 2015, 71, 676-685
Fresno, N.; Macías-Gonzalez, M.; Torres-Zaguirre, A.; Romero-Cuevas, M.; Sanz-Camacho, P.; Elguero, J.; Pavon,́ F.J.; Rodríguez de Fonseca, F.; Goya, P.; Pérez-Fernández, R.
[2015]. Novel oxazolidinone-based peroxisome proliferator activated receptor agonists: molecular modeling, synthesis, and biological evaluation. J. Med. Chem, 2015, 58, 6639-6652.
Morales-García, J. A.; Palomo, V.; Redondo, M.; Alonso-Gil, S.; Gil, C.; Martinez, A.; Perez-Castillo, A.
[2014]. Crosstalk between phosphodiesterase 7 and glycogen synthase kinase-3, two relevant therapeutic targets for neurological disorders. ACS Chem. Neurosci. 2014, 5, 194-204
Garcia, A. M.; Redondo, M.; Martinez, A.; Gil, C.
[2014]. Phosphodiesterase 10 inhibitors: A new strategy for Parkinson’s disease pharmacological therapy. Curr. Med. Chem. 2014, 10, 1171-1187
Salado, I. G.; Redondo, M.; Bello, M. L.; Perez, C.; Liachko, N. F.; Kraemer, B. C.; Miguel, L.; Lecourtois, M.; Gil, C.; Martinez, A.; Perez, D. I.
[2014]. Protein kinase CK-1 inhibitors as new potential drugs for Amyotrophic Lateral Sclerosis. J. Med. Chem. 2014, 57, 2755-2772
Gonzalez-Naranjo, P.; Perez-Macias, N.; Campillo, N. E.; Perez, C.; Aran, V. J.; Giron, R.; Sanchez-Robles, E.; Martin, M. I.; Gomez-Canas, M.; Garcia-Arencibia, M.; Fernandez- Ruiz, J.; Paez, J. A.,
[2014]. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease. Eur J Med Chem, 2014, 73, 56-72
Pérez, C.; Ruiz del Castillo, M. L.; Gil, C.; Blanch, G. P.; Flores, G.
[2014]. Anthocyanins constituents, antioxidant and anti-Inflammatory activity of strawberries. Comparison with other berry fruits. En Strawberries: Cultivation, antioxidant properties and health benefits. Ed. N. Malone. Nova Science Publishers, Inc. 2014, 39-54.
González-Muñoz, M.; Rodríguez-Mahillo, A. I.; Gil, C.; Morán, Y.; Moneo, I.; Martínez, A.; Mora, J. S.
[2014]. Glycogen synthase kinase-3β expression and phosphorylation in peripheral blood mononuclear cells of patients with Amyotrophic Lateral Sclerosis. Br. J. Med. Med. Res. 2014, 4, 263-271
García, A. M.; Brea, J.; Morales-García, J. A.; Perez, D. I.; González, A.; Alonso-Gil, S.; Gracia-Rubio, I.; Ros-Simó, C.; Conde, S.; Cadavid, M. I.; Loza, M. I.; Perez-Castillo, A.; Valverde, O.; Martinez, A.; Gil, C.
[2014]. Modulation of cAMP specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors. J. Med. Chem. 2014, 57, 8590-8607
Martinez, A.; Gil, C.
[2014]. cAMP specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases. Exp. Opin. Ther. Patents 2014, 24, 1311-1321.
Salado IG, Redondo M, Bello ML, Perez C, Liachko NF, Kraemer BC, Miguel L, Lecourtois M, Gil C, Martinez A, Perez DI
[2014]. Protein kinase CK-1 inhibitors as new potential drugs for Amyotrophic Lateral Sclerosis. J. Med. Chem. 73:56-72
P. Gonzalez-Naranjo, N. Perez-Macias, N. E. Campillo, C. Perez, V. J. Aran, R. Giron, E. Sanchez-Robles, M. I. Martin, M. Gomez-Canas, M. Garcia-Arencibia, J. Fernandez-Ruiz and J. A. Paez
[2014]. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer´s disease. Eur J Med Chem 73: 56-72
Lipina, T. V.; Palomo, V.; Gil, C.; Martinez, A.; Roder, J. C.
[2013]. Dual inhibitor of PDE7 and GSK-3 - VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice. Neuropharmacology 2013, 64, 205-214
